ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer
A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers
Sponsor: Adherex Technologies, Inc.
A PHASE1 clinical study on Ampulla of Vater Adenocarcinoma and Gallbladder Adenocarcinoma, this trial is completed. The trial is conducted by Adherex Technologies, Inc. and has accumulated 9 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Oct 2023 — Jan 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Oct 2023 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Feb 2017 — Feb 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Adherex Technologies, Inc.
- National Cancer Institute (NCI)
- University of Nebraska
For direct contact, visit the study record on ClinicalTrials.gov .